FDA Gives Pharmaxis Green Light to Start Myelofibrosis Phase 2 Study

19th Aug 20

Release Date: 19/08/2020 12:33pm

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) announced that the Food and Drug Administration (FDA) has completed a safety review of the company’s Investigational New Drug (IND) application for the pan-LOX inhibitor PXS-5505 and given Pharmaxis permission to proceed with a phase 1/2 clinical trial for the treatment of myelofibrosis in adults. 

Read full media release - pdf

Categories: News and Media